Drug selection for colorectal cancer therapy using antibody-based arrays
AssigneePrometheus Laboratories Inc.
InventorsPhillip Kim, Sharat Singh
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy.
Claims26
A method for selecting a suitable anticancer drug for the treatment of a colorectal cancer, the method comprising:
- (a) determining the expression level and/or activation level of one or more analytes selected from the group consisting of HER1, HER2, HER3, cMET, cKIT, IGF-1R, PI3K, AKT, ERK, SHC, and combinations thereof in a cellular extract produced from an isolated cancer cell;
- and
- (b) selecting a suitable anticancer drug for the treatment of the colorectal cancer based upon the expression level and/or activation level of the one or more analytes determined in step (a).
A method for identifying the response of a colorectal cancer to treatment with an anticancer drug, the method comprising:
- (a) determining the expression level and/or activation level of one or more analytes selected from the group consisting of HER1, HER2, HER3, cMET, cKIT, IGF-1R, PI3K, AKT, ERK, SHC, and combinations thereof in a cellular extract produced from an isolated cancer cell;
- and
- (b) identifying the response of the colorectal cancer to treatment with an anticancer drug based upon the expression level and/or activation level of the one or more analytes determined in step (a).
A method for predicting the response of a subject having a colorectal cancer to treatment with an anticancer drug, the method comprising:
- (a) determining the expression level and/or activation level of one or more analytes selected from the group consisting of HER1, HER2, HER3, cMET, cKIT, IGF-1R, PI3K, AKT, ERK, SHC, and combinations thereof in a cellular extract produced from an isolated cancer cell;
- and
- (b) predicting the response of the subject having the colorectal cancer to treatment with an anticancer drug based upon the expression level and/or activation level of the one or more analytes determined in step (a).
Dependencies are inferred from the claim text.